Mckesson Corp (NYSE:MCK) Institutional Investor Sentiment Trend

McKesson Corporation (NYSE:MCK) Logo

Sentiment for Mckesson Corp (NYSE:MCK)

Mckesson Corp (NYSE:MCK) institutional sentiment decreased to 0.81 in Q2 2019. Its down -0.22, from 1.03 in 2019Q1. The ratio fall, as 245 institutional investors increased and started new holdings, while 304 cut down and sold their stakes in Mckesson Corp. The institutional investors in our partner’s database now possess: 154.39 million shares, down from 161.85 million shares in 2019Q1. Also, the number of institutional investors holding Mckesson Corp in their top 10 holdings increased from 7 to 14 for an increase of 7. Sold All: 41 Reduced: 263 Increased: 182 New Position: 63.

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. The company has market cap of $26.54 billion. The firm operates in two divisions, McKesson Distribution Solutions and McKesson Technology Solutions. It has a 46.66 P/E ratio. The McKesson Distribution Solutions segment distributes branded and generic pharmaceutical drugs, and other healthcare-related products; and provides practice management, technology, clinical support, and business solutions to community oncology and other specialty practices.

The stock decreased 1.76% or $2.57 during the last trading session, reaching $143.53. About 1.79M shares traded or 21.17% up from the average. McKesson Corporation (NYSE:MCK) has risen 10.37% since September 13, 2018 and is uptrending. It has outperformed by 10.37% the S&P500.

Analysts await McKesson Corporation (NYSE:MCK) to report earnings on October, 24. They expect $3.57 earnings per share, down 0.83 % or $0.03 from last year’s $3.6 per share. MCK’s profit will be $660.10M for 10.05 P/E if the $3.57 EPS becomes a reality. After $3.31 actual earnings per share reported by McKesson Corporation for the previous quarter, Wall Street now forecasts 7.85 % EPS growth.

Krensavage Asset Management Llc holds 16.28% of its portfolio in McKesson Corporation for 373,297 shares. Kiltearn Partners Llp owns 1.73 million shares or 7.36% of their US portfolio. Moreover, Knightsbridge Asset Management Llc has 6.5% invested in the company for 70,161 shares. The Ontario – Canada-based Portland Investment Counsel Inc. has invested 6.45% in the stock. Glenview Capital Management Llc, a New York-based fund reported 4.51 million shares.

McKesson Corporation (NYSE:MCK) Ratings Coverage

Ratings analysis reveals 20% of McKesson’s analysts are positive. Out of 5 Wall Street analysts rating McKesson, 1 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $13500 while the high is $16400. The stock’s average target of $149.80 is 4.37% above today’s ($143.53) share price. MCK was included in 8 notes of analysts from March 20, 2019. The stock of McKesson Corporation (NYSE:MCK) earned “Equal-Weight” rating by Morgan Stanley on Tuesday, August 27. As per Monday, July 22, the company rating was maintained by Credit Suisse. The stock of McKesson Corporation (NYSE:MCK) earned “Overweight” rating by JP Morgan on Monday, July 22.

More notable recent McKesson Corporation (NYSE:MCK) news were published by: Seekingalpha.com which released: “J&J opioid ruling a relief for shareholders but others may not benefit – WSJ – Seeking Alpha” on August 26, 2019, also Gurufocus.com with their article: “Seth Klarman’s Favorite Health Care Stocks – GuruFocus.com” published on September 12, 2019, Finance.Yahoo.com published: “Why McKesson Corporation’s (NYSE:MCK) Return On Capital Employed Is Impressive – Yahoo Finance” on May 31, 2019. More interesting news about McKesson Corporation (NYSE:MCK) were released by: Seekingalpha.com and their article: “Wall Street Breakfast: J&J Gains After Favorable Opioid Ruling – Seeking Alpha” published on August 27, 2019 as well as Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For September 12, 2019 – Benzinga” with publication date: September 12, 2019.

McKesson Corporation (NYSE:MCK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.